Literature DB >> 22406457

Efficacy of a Gal-lectin subunit vaccine against experimental Entamoeba histolytica infection and colitis in baboons (Papio sp.).

Mohamed D Abd Alla1, Roman Wolf, Gary L White, Stanley D Kosanke, David Cary, Jaco J Verweij, Mie-Jie Zhang, Jonathan I Ravdin.   

Abstract

To determine the efficacy of a Gal-lectin based intranasal synthetic peptide vaccine, we developed a new experimental primate model of Entamoeba histolytica intestinal infection. Release of xenic E. histolytica trophozoites (5×10(6)) into the small bowel of baboons (Papio sp.) resulted in a rapid intestinal anti-amebic antibody response and a brief infection; however, release of trophozoites directly into the cecum (5 baboons) elicited a sustained E. histolytica infection, as determined by quantitative fecal PCR, and an ulcerative, inflammatory colitis observed on colonoscopy and histopathology. In three controlled experiments, baboons received four immunizations at seven day intervals of 1600 μg of the vaccine/nostril, with Cholera toxin, 20 μg/nostril as adjuvant; vaccinated (n=6) and control baboons (n=6) baboons were then challenged via colonoscopy with xenic trophozoites (5×10(6)). During 90 days of follow up, 250 of 415 (60.24%) fecal samples in control baboons had a (+) PCR for E. histolytica, compared to only 36 of 423 (8.51%) samples from vaccinated baboons (P<0.001). All 6 vaccinated baboons were free of infection by the 51st day after challenge, 5 of 6 controls positive had (+) fecal PCRs for up to 126 days post-challenge (P=0.019). Inflammatory colitis developed in 4 of 6 control baboons post-challenge, with invasive E. histolytica trophozoites present in 2 of the 4 on histopathology. There was no evidence of inflammatory colitis or parasite invasion in any of the vaccinated baboons; there was a strong inverse correlation between positive ELISA OD value indicating the presence of intestinal anti-peptide IgA antibodies and baboons having a positive fecal PCR CT value, P<0.001. In conclusion, we developed a novel primate model of E. histolytica intestinal infection and demonstrated that a Gal-lectin-based intranasal synthetic peptide vaccine was highly efficacious in preventing experimental E. histolytica infection and colitis in baboons.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22406457     DOI: 10.1016/j.vaccine.2012.02.066

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  16 in total

Review 1.  Entamoeba histolytica: a snapshot of current research and methods for genetic analysis.

Authors:  Laura Morf; Upinder Singh
Journal:  Curr Opin Microbiol       Date:  2012-06-02       Impact factor: 7.934

2.  Nanoformulation of synergistic TLR ligands to enhance vaccination against Entamoeba histolytica.

Authors:  Mayuresh M Abhyankar; Zannatun Noor; Mark A Tomai; James Elvecrog; Christopher B Fox; William A Petri
Journal:  Vaccine       Date:  2017-01-12       Impact factor: 3.641

Review 3.  The future for vaccine development against Entamoeba histolytica.

Authors:  Jeanie Quach; Joëlle St-Pierre; Kris Chadee
Journal:  Hum Vaccin Immunother       Date:  2014-02-06       Impact factor: 3.452

4.  Immunization with the Entamoeba histolytica surface metalloprotease EhMSP-1 protects hamsters from amebic liver abscess.

Authors:  Eduardo C Roncolato; José E Teixeira; José E Barbosa; Leandra N Zambelli Ramalho; Christopher D Huston
Journal:  Infect Immun       Date:  2014-12-01       Impact factor: 3.441

Review 5.  The dynamic interdependence of amebiasis, innate immunity, and undernutrition.

Authors:  Hans P Verkerke; William A Petri; Chelsea S Marie
Journal:  Semin Immunopathol       Date:  2012-11-01       Impact factor: 9.623

Review 6.  Host immune response to intestinal amebiasis.

Authors:  Shannon N Moonah; Nona M Jiang; William A Petri
Journal:  PLoS Pathog       Date:  2013-08-22       Impact factor: 6.823

7.  Species-specific immunity induced by infection with Entamoeba histolytica and Entamoeba moshkovskii in mice.

Authors:  Chikako Shimokawa; Richard Culleton; Takashi Imai; Kazutomo Suzue; Makoto Hirai; Tomoyo Taniguchi; Seiki Kobayashi; Hajime Hisaeda; Shinjiro Hamano
Journal:  PLoS One       Date:  2013-11-29       Impact factor: 3.240

8.  Proteases from Entamoeba spp. and Pathogenic Free-Living Amoebae as Virulence Factors.

Authors:  Jesús Serrano-Luna; Carolina Piña-Vázquez; Magda Reyes-López; Guillermo Ortiz-Estrada; Mireya de la Garza
Journal:  J Trop Med       Date:  2013-02-07

Review 9.  G protein signaling in the parasite Entamoeba histolytica.

Authors:  Dustin E Bosch; David P Siderovski
Journal:  Exp Mol Med       Date:  2013-03-22       Impact factor: 8.718

10.  Evaluation of the C-Terminal Fragment of Entamoeba histolytica Gal/GalNAc Lectin Intermediate Subunit as a Vaccine Candidate against Amebic Liver Abscess.

Authors:  Xiangyang Min; Meng Feng; Yue Guan; Suqin Man; Yongfeng Fu; Xunjia Cheng; Hiroshi Tachibana
Journal:  PLoS Negl Trop Dis       Date:  2016-01-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.